Navigation Links
Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
Date:11/6/2008

8 (p < 0.0001) and 20.7 at Week 16 (p = 0.02). Immune monitoring performed in three of four patients who underwent repeat treatment suggested an increase in immune response following the booster treatments. Five patients had prolonged disease stabilization ranging from 48 to 94 weeks, without the addition of other cancer therapy other than the continuation of bisphosphonates. In addition, one patient experienced a partial response lasting approximately six months.

"We were pleased to see consistent results across both NEUVENGE trials, particularly as they further substantiate the tolerability of this therapeutic approach," stated Mark Frohlich, M.D., senior vice president, clinical affairs and chief medical officer. "These data provide further evidence of the promise of our active cellular immunotherapy platform which also includes PROVENGE(R) (sipuleucel-T), our lead product candidate currently in late-stage development for prostate cancer. We expect to receive the final data analysis from our ongoing Phase 3 PROVENGE trial in mid-2009 and look forward to discussing further clinical development plans for NEUVENGE and our immunotherapy pipeline after that time."

About NEUVENGE

NEUVENGE (lapuleucel-T) is an investigational product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to stimulate a patient's own immune system. ACIs hold promise because they may provide patients with a meaningful clinical benefit with low toxicities. NEUVENGE is designed to stimulate cellular immune responses against HER2/neu. HER2/neu is over-expressed in a variety of solid tumors, including breast, colorectal, bladder and ovarian cancer. In clinical studies, patients typically received three infusions over a one-month period as a complete course of therapy.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commerc
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... -- Top Staten Island Pediatrician Dr. Michael ... which discusses tips for parents about pool safety for children. ... According to US News article, "Drowning is the ... aged 1 to 4, and can occur in as little ... the article says that watching a child in the water ...
(Date:7/23/2014)... July 23, 2014 PositiveID Corp. (OTCQB: PSID), ... , is an emerging player in the bio-threat ... bio-threat detection and rapid medical testing. The Company,s ... Bio-agent Autonomous Networked Detector), was developed under contract ... Science & Technology directorate, and $30 million of ...
(Date:7/23/2014)... Korea , July 23, 2014  Mezzion Pharma ... program to evaluate the use of udenafil to treat ... single ventricle heart defects. The clinical program will follow ... of the Pediatric Heart Network (PHN), a multi-center clinical ... Blood Institute (NHLBI) of the National Institutes of Health ...
Breaking Medicine Technology:Premier Staten Island Pediatrician Dr. Michael Gabriel Comments On Article Discussing Pool Safety Tips for Parents 2PositiveID Analyst Inspection: Emerging Contender in BioThreat Detection - First Ever Revenue Guidance and Backlog Position Company for Increased Visibility and Traction - by SmallCapTraders.com 2Mezzion Pharma Initiates Clinical Development Program To Evaluate Udenafil In Adolescents With Single Ventricle Heart Defects 2
... KINGSTOWN, R.I., Sept. 7, 2011 Prescription monitoring ... a new comprehensive program, its Safe Use Treatment ... Management, Safe Use is compliant with the FDA,s ... individual State Prescribing Regulations for controlled substances.  The ...
... NanoSmart™ Pharmaceuticals, Inc., a biopharmaceutical corporation developing ... corporate facility located in Laguna Hills, CA.  The ... necessary to begin formal development of its initial ... us a physical presence in Orange County, California ...
Cached Medicine Technology:Dominion Diagnostics Leads Fight Against Prescription Drug Abuse with Safe Use Treatment Monitoring Solution 2NanoSmart™ Pharmaceuticals, Inc., Opens New Headquarters - Begins Development of New Drug Delivery Platform for Cancer 2
(Date:7/23/2014)... checking the pulse of a stroke survivor may help ... the method of choice for checking for irregular heartbeat ... a stroke. Our study shows it may be a ... who might need more thorough monitoring to prevent a ... Erlangen University in Germany. The study included ...
(Date:7/23/2014)... Imaging and Bioengineering will host its second Edward C. ... the NIH campus. There will be ten exciting presentations ... NIBIB-funded research. , WHO: , ... Optical Voltage Sensor, Quyen Nguyen, Univ. of California, ... Imaging during Surgery, Jan Grimm, ...
(Date:7/23/2014)... Angeles, CA (PRWEB) July 23, 2014 ... practices delivering Enhanced External Counterpulsation (EECP), is ... who receives EECP therapy at the health center. ... ischemic heart disease. Since receiving ongoing EECP therapy since ... , When Sara Soulati, CEO of Global Cardio Care, ...
(Date:7/23/2014)... Fragile X syndrome ( FXS ) is a ... other behaviors on the autistic spectrum, as well as ... of mental impairment and the most common cause of ... California, Riverside have published a study that ... FXS. Appearing online today (July 23) in the ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 Four hospitals ... been lauded in the latest ranking of the country’s ... . Released online today and slated for publication ... recognizes Allegheny General Hospital (AGH), Forbes Hospital, Saint Vincent ... centers across multiple clinical specialties. , “There ...
Breaking Medicine News(10 mins):Health News:Routine Pulse Check May Prevent Second Stroke, Study Says 2Health News:Global Cardio Care Celebrates EECP Patient’s 100th Birthday 2Health News:Study links enzyme to autistic behaviors 2Health News:Study links enzyme to autistic behaviors 3Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 2Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 3
... May 21 This year 28 students in 17 states ... sponsored by the Centers for Disease Control and Prevention and ... invites fifth- and sixth-grade students to create posters that encourage ... and the diseases they can cause. Downloadable files of the ...
... 21 For the second year in a row, the ... blood through the Red Cross by joining Red Cross ... Racing is a program designed to increase the number ... Participants of this program can get points for a variety ...
... quarter of those seeking treatment are addicted to the ... -- More pregnant women in drug treatment programs are ... new research shows. , The number of expectant mothers ... 2006. In 1994, methamphetamine use accounted for 8 percent ...
... "Stem cell research and regenerative medicine are in an ... very fast and many companies are being formed and ... Jonas Frisn. , As an example, a first-in-human study ... drug product, sNN0031, from the Swedish company NeuroNova. The ...
... May 21 Three HealthEast hospitals in the ... the federal government a total of $2.28 million ... Medicare fraud involving a certain type of spinal ... first hospitals to settle charges stemming from a ...
... researchers have found that bipolar disorder is more costly ... or coronary artery disease. These findings are based on ... costs (the costs of seeing any specialist and all ... of this review are being presented today at the ...
Cached Medicine News:Health News:'Fight the Bite' Poster Contest Honors 28 Students in 17 States 2Health News:'Fight the Bite' Poster Contest Honors 28 Students in 17 States 3Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 2Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 3Health News:Methamphetamine Use Triples Among Pregnant Rehab Patients 2Health News:Methamphetamine Use Triples Among Pregnant Rehab Patients 3Health News:Minnesota Hospitals Pay $2.28 Million to Settle Medicare Fraud Charges Involving Kyphoplasty 2Health News:Minnesota Hospitals Pay $2.28 Million to Settle Medicare Fraud Charges Involving Kyphoplasty 3
... supports interventional cardioangiography procedures with MR imaging ... cardioangiography system., Utilize your angio and MR ... our integrated suite. Because the systems can ... diagnosis and follow-up in one room, one ...
... a comprehensive medical billing software capable ... multiple payer requirements of healthcare billing ... functionality to necessary to process claims ... such as trip reporting for ambulance ...
... code the charge while completing a chart note, ... from office, both directly feeding the charge entry ... Form/Superbill, data entry can be done with our ... are posted by reflecting open item charges, and ...
The HearTwave system is the original stand-alone Microvolt T-Wave Alternans (MTWA) testing platform....
Medicine Products: